A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms
Latest Information Update: 28 Dec 2021
At a glance
- Drugs Sarizotan (Primary)
- Indications Rett syndrome
- Focus Registrational; Therapeutic Use
- Acronyms STARS
- Sponsors Newron Pharmaceuticals
- 05 Nov 2020 Status changed from completed to discontinued.
- 05 Sep 2020 This trial has been discontinued in Unite kingdom, according to European Clinical Trials Database record.
- 04 May 2020 According to a Newron Pharmaceuticals media release,Newron has decided to terminate this development program.